B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? (Q37641025)

21 August 2017

1 reference

title

B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? (English)

1 reference

21 August 2017

Catarina Favas

1

1 reference

21 August 2017

David A Isenberg

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Nature Reviews Rheumatology

21 August 2017

published in

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

711-716

1 reference

Systemic lupus erythematosus.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Effects of rituximab on resistant SLE disease including lung involvement.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

An open study of B lymphocyte depletion in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Connective tissue diseases: The conundrum of B cell depletion in SLE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.218

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19946298

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19946298

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2009.218

1 reference

21 August 2017

1 reference